Strata Critical Medical vs Viemed Healthcare
SRTA and VMD side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How SRTA and VMD compare
Strata Critical Medical and Viemed Healthcare are about the same size, with market caps of $393M and $368M.
On earnings, Strata Critical Medical is cheaper: it trades at 8.7× trailing earnings, against 26.9× for Viemed Healthcare.
Strata Critical Medical grew revenue faster over the last twelve months (66.8% versus 25.2% for Viemed Healthcare).
Strata Critical Medical keeps more of each dollar of sales as profit, with a net margin of 15.7% compared with 4.8% at Viemed Healthcare.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | SRTA | VMD |
|---|---|---|
| Size and price | ||
| Market cap | $393M | $368M |
| Share price | $4.44 | $9.67 |
| Change, 1 year | −12.1% | 47.9% |
| Change, 5 years | −56.0% | 59.0% |
| Beta (5Y) | 1.69 | 0.57 |
| Employees | 601 | 1,382 |
| StockData Score | ||
| Total score | 17 | 17 |
| Valuation score | 4 | 4 |
| Growth score | 4 | 5 (better) |
| Performance score | 3 | 3 |
| Health score | 6 (better) | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 8.7× (better) | 26.9× |
| P/S | 1.5× | 1.2× (better) |
| P/B | 1.4× (better) | 2.6× |
| EV/EBITDA | – | 9.5× |
| P/FCF | – | 12.6× |
| PEG | – | 0.83 |
| FCF yield | −12.3% | 7.9% (better) |
| Fair value | $11.19 | $10.78 |
| Margin of safety | 60.3% (better) | 10.3% |
| Growth | ||
| Revenue growth (TTM) | 66.8% (better) | 25.2% |
| Revenue growth, 5Y average | 44.6% (better) | 15.5% |
| Net income growth (TTM) | – | 3.7% |
| EPS growth (TTM) | – | 5.9% |
| EPS growth, 5Y average | – | −13.9% |
| Profitability | ||
| Gross margin | 20.6% | 57.5% (better) |
| Operating margin | −8.0% | 7.5% (better) |
| Net margin | 15.7% (better) | 4.8% |
| FCF margin | −18.9% | 9.7% (better) |
| Return on equity | 16.0% (better) | 10.2% |
| Return on invested capital | −8.8% | 12.2% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.05 (better) |
| Net debt / EBITDA | – | −0.09 |
| Current ratio | 2.64 (better) | 1.13 |
| Altman Z-score | 4.61 | 6.42 (better) |
| Piotroski F-score | 5 | 5 |
| Dividends and buybacks | ||
| Buyback yield | – | 5.0% |
| Shareholder yield | 0.00% | 5.0% (better) |
| Ownership | ||
| Held by institutions | 63.0% | 71.3% |
| Held by insiders | 20.9% | 15.4% |
| Insider net buying, 12 months | −$830K (better) | −$1.6M |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 6.2% | 4.9% |
Go deeper
- SRTA stock overview
- SRTA income statement
- SRTA valuation and score
- VMD stock overview
- VMD income statement
- VMD valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.